Dongbin Bi

502 total citations
19 papers, 390 citations indexed

About

Dongbin Bi is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Dongbin Bi has authored 19 papers receiving a total of 390 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Molecular Biology, 8 papers in Pulmonary and Respiratory Medicine and 6 papers in Cancer Research. Recurrent topics in Dongbin Bi's work include Renal cell carcinoma treatment (5 papers), Bladder and Urothelial Cancer Treatments (3 papers) and Renal and related cancers (3 papers). Dongbin Bi is often cited by papers focused on Renal cell carcinoma treatment (5 papers), Bladder and Urothelial Cancer Treatments (3 papers) and Renal and related cancers (3 papers). Dongbin Bi collaborates with scholars based in China and Australia. Dongbin Bi's co-authors include Kejia Ding, Shuai Liu, Sentai Ding, Jiajü Lü, Zhihong Niu, Hao Ning, Liang Sun, Meifang He, Yonghui Wang and Yanyan Jiang and has published in prestigious journals such as PLoS ONE, Experimental Cell Research and Materials & Design.

In The Last Decade

Dongbin Bi

19 papers receiving 389 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Dongbin Bi China	12	195	87	71	67	64	19	390
Xin Jiao China	13	146 0.7×	171 2.0×	62 0.9×	32 0.5×	84 1.3×	41	500
Christin Neuber Germany	12	222 1.1×	129 1.5×	46 0.6×	38 0.6×	104 1.6×	43	573
Zoi Kanaki Greece	9	253 1.3×	60 0.7×	67 0.9×	47 0.7×	109 1.7×	19	510
Julia Chang United States	10	382 2.0×	57 0.7×	88 1.2×	31 0.5×	63 1.0×	12	506
Zeyuan Zhong China	12	262 1.3×	87 1.0×	126 1.8×	122 1.8×	51 0.8×	23	495
Zarema Gilazieva Russia	11	205 1.1×	99 1.1×	72 1.0×	26 0.4×	94 1.5×	17	391
Zeze Fu China	7	242 1.2×	112 1.3×	88 1.2×	88 1.3×	166 2.6×	12	537
Shupei Qiao China	16	225 1.2×	135 1.6×	59 0.8×	28 0.4×	85 1.3×	32	467
Somaiah Chinnapaka United States	9	106 0.5×	105 1.2×	36 0.5×	30 0.4×	51 0.8×	14	432

Countries citing papers authored by Dongbin Bi

Since Specialization

Citations

This map shows the geographic impact of Dongbin Bi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dongbin Bi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dongbin Bi more than expected).

Fields of papers citing papers by Dongbin Bi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dongbin Bi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dongbin Bi. The network helps show where Dongbin Bi may publish in the future.

Co-authorship network of co-authors of Dongbin Bi

This figure shows the co-authorship network connecting the top 25 collaborators of Dongbin Bi. A scholar is included among the top collaborators of Dongbin Bi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dongbin Bi. Dongbin Bi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

Dong, Wei, Jiajü Lü, Zhao Zhang, et al.. (2021). βKlotho Inhibits Cell Proliferation by Downregulating ELK4 and Predicts Favorable Prognosis in Prostate Cancer. Cancer Management and Research. Volume 13. 6377–6387. 3 indexed citations

Liu, Shuai, Xiaoli Liu, Fei Wu, et al.. (2019). HADHA overexpression disrupts lipid metabolism and inhibits tumor growth in clear cell renal cell carcinoma. Experimental Cell Research. 384(1). 111558–111558. 21 indexed citations

Wang, Yonghui, Liang Sun, Zhigang Mei, et al.. (2019). 3D printed biodegradable implants as an individualized drug delivery system for local chemotherapy of osteosarcoma. Materials & Design. 186. 108336–108336. 103 indexed citations

Sun, Liang, Jiajü Lü, Sentai Ding, et al.. (2017). HCRP1 regulates proliferation, invasion, and drug resistance via EGFR signaling in prostate cancer. Biomedicine & Pharmacotherapy. 91. 202–207. 7 indexed citations

Wang, Zhiyang, Shuai Liu, Kejia Ding, et al.. (2016). Silencing Livin induces apoptotic and autophagic cell death, increasing chemotherapeutic sensitivity to cisplatin of renal carcinoma cells. Tumor Biology. 37(11). 15133–15143. 10 indexed citations

Wang, Xiaoqing, Zhihong Niu, Jia Yang, et al.. (2016). Ubenimex inhibits cell proliferation, migration and invasion by inhibiting the expression of APN and inducing autophagic cell death in prostate cancer cells. Oncology Reports. 35(4). 2121–2130. 29 indexed citations

Bi, Dongbin, et al.. (2016). miR-1301 promotes prostate cancer proliferation through directly targeting PPP2R2C. Biomedicine & Pharmacotherapy. 81. 25–30. 23 indexed citations

Wu, Fei, Sentai Ding, Xin Li, et al.. (2016). Elevated expression of HIF-lα in actively growing prostate tissues is associated with clinical features of benign prostatic hyperplasia. Oncotarget. 7(11). 12053–12062. 14 indexed citations

Liu, Shuai, Chensheng Li, Sentai Ding, et al.. (2016). CYLD downregulates Livin and synergistically improves gemcitabine chemosensitivity and decreases migratory/invasive potential in bladder cancer: the effect is autophagy-associated. Tumor Biology. 37(9). 12731–12742. 11 indexed citations

10.

Liu, Shuai, Xiaoqing Wang, Jiajü Lü, et al.. (2016). Ubenimex enhances the radiosensitivity of renal cell carcinoma cells by inducing autophagic cell death. Oncology Letters. 12(5). 3403–3410. 12 indexed citations

11.

Sun, Liang, Jiajü Lü, Zhihong Niu, et al.. (2015). A Potent Chemotherapeutic Strategy with Eg5 Inhibitor against Gemcitabine Resistant Bladder Cancer. PLoS ONE. 10(12). e0144484–e0144484. 29 indexed citations

12.

Bi, Dongbin, et al.. (2015). Gene expression patterns combined with network analysis identify hub genes associated with bladder cancer. Computational Biology and Chemistry. 56. 71–83. 42 indexed citations

13.

Ye, Changjiang, et al.. (2015). Invasive Epithelioid Angiomyolipoma with Tumor Thrombus in the Inferior Vena Cava: A Case Report and Literature Review. Urologia Internationalis. 98(1). 120–124. 14 indexed citations

14.

Liu, Shuai, Liping Han, Xiaoqing Wang, et al.. (2015). Nephroblastoma overexpressed gene (NOV) enhances RCC cell motility through upregulation of ICAM-1 and COX-2 expression via Akt pathway.. PubMed. 8(2). 1302–11. 11 indexed citations

15.

Ding, Sentai, Zuohui Zhao, Fei Wu, et al.. (2014). Eg5 inhibitor, a novel potent targeted therapy, induces cell apoptosis in renal cell carcinoma. Tumor Biology. 35(8). 7659–7668. 9 indexed citations

16.

Lü, Jiajü, Kejia Ding, Dongbin Bi, et al.. (2013). The expression of Eg5 predicts a poor outcome for patients with renal cell carcinoma. Medical Oncology. 30(1). 476–476. 33 indexed citations

17.

Lü, Jiajü, et al.. (2013). Metastatic renal cell carcinoma to vagina and review of literature. Chinese Medical Journal. 126(9). 1793–1793. 3 indexed citations

18.

Liu, Shuai, Zheng Liu, Dongbin Bi, et al.. (2012). CCN3 (NOV) regulates proliferation, adhesion, migration and invasion in clear cell renal cell carcinoma. Oncology Letters. 3(5). 1099–1104. 15 indexed citations

19.

Sun, Xiaowen, et al.. (2008). Management of primary T1G3 bladder cancer: immediate cystectomy or bladder preserving approach?. 29(12). 811–814. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact